Pharma Shares Shine as Divi's Laboratories and Laurus Labs Hit New Highs, Up to 91% in FY27

Pharma shares extended their strong run on Wednesday, August 26, 2026, with Divi's Laboratories and Laurus Labs hitting fresh highs. Both stocks have zoomed up to 91% in FY27, reflecting robust momentum across India's pharmaceutical and active pharmaceutical ingredient (API) manufacturing sector.

Click Here – Get Free Investment Predictions

About Divi's Laboratories and Laurus Labs

Divi's Laboratories is one of India's leading API and custom synthesis manufacturers, supplying pharmaceutical intermediates and active ingredients to global innovator and generic drug companies. Laurus Labs similarly operates in the API and contract development and manufacturing organisation (CDMO) space, with a growing presence in complex generics and specialty pharmaceutical ingredients.

What Is Driving the Pharma Sector Rally?

Track pharma sector stocks on the Univest Screener

A sector-wide rally that has pushed stocks like Divi's Laboratories and Laurus Labs up to 91% in FY27 typically reflects a combination of factors, including strong order books from global pharmaceutical clients, improving margins from better fixed-cost absorption as capacity utilisation increases, and favourable currency movements that boost export realisations for India's pharma exporters.

India's API and CDMO manufacturers have also benefited from a broader global trend of supply chain diversification, as innovator pharmaceutical companies look to reduce over-reliance on any single manufacturing geography, creating incremental order flow opportunities for established Indian players.

Pharma Stocks Performance Data

Stock	FY27 Performance	Recent Milestone
Divi's Laboratories	Up to 91% in FY27	New high
Laurus Labs	Up to 91% in FY27	New high

Key Risks to Watch

After a rally of this magnitude, investors should watch for potential profit booking and monitor whether earnings growth in subsequent quarters can justify the re-rating. Global pharmaceutical pricing pressure, regulatory inspection outcomes at manufacturing facilities, and currency volatility remain ongoing risks for API and CDMO-focused companies.

Conclusion

Pharma shares, led by Divi's Laboratories and Laurus Labs hitting new highs with FY27 gains of up to 91%, reflect strong sector-wide momentum driven by robust order books and improved cost absorption. Investors should track upcoming quarterly results to confirm whether earnings growth supports the sector's current valuations. Consult a SEBI-registered financial advisor before making any investment decision.

Download the Univest iOS App or Univest Android App to track pharma sector stocks and quarterly earnings.

FAQs on Pharma Shares

Why are pharma shares like Divi's and Laurus Labs hitting new highs?

Ans. Divi's Laboratories and Laurus Labs are hitting new highs amid a broader pharma sector rally driven by strong order books, improving margins from better fixed-cost absorption, and favourable currency movements boosting export realisations.

How much have these pharma stocks gained in FY27?

Ans. Divi's Laboratories and Laurus Labs have both gained up to 91% in FY27, reflecting robust momentum across India's pharmaceutical and API manufacturing sector.

What business do Divi's Laboratories and Laurus Labs operate?

Ans. Divi's Laboratories is a leading API and custom synthesis manufacturer supplying pharmaceutical intermediates to global drug companies. Laurus Labs operates in a similar API and CDMO space with a growing presence in complex generics.

What is driving the broader pharma sector rally in India?

Ans. The pharma sector rally is being driven by strong order books from global clients, improving operating margins, favourable currency movements, and a global trend of supply chain diversification benefiting established Indian API and CDMO manufacturers.

Are pharma stocks a good investment after this rally?

Ans. After a significant rally, investors should assess whether future earnings growth can justify current valuations. Risks include pricing pressure, regulatory inspection outcomes, and currency volatility. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decision.